Table 1.

Demographic and Clinicopathologic Comparison of the Patients with t-MDS with or without Moderate/Severe Bone Marrow Fibrosis

	Bone Marrow Fibrosis		p
	(MF 0–1) (n=219)	(MF 2–3) (n=47)
Age (Years)	64 (22–88)	64 (18–79)	0.603
Gender (Male/Female)	124/95	28/19	0.419
Cancer history
Hematopoietic malignance	152 (69.4%)	23 (48.9%)	0.027
Solid tumor	62 (28.3%)	22 (46.8%)
Non malignant disease	5 (2.3%)	2 (4.3%)
Prior Treatment for cancer
Radiation only	5 (2.3%)	6 (12.8%)	0.004
Chemotherapy only	155 (70.8%)	28 (59.6%)
Chemotherapy and radiation	59 (26.9%)	13 (27.7%)
Peripheral blood
• White blood cell count (×10 9/L)	3.0	2.9	0.872
• Absolute neutrophil count (×109/L)	1.4	1.3	0.872
• Hemoglobin (g/dL)	9.8 (6.8–16.0)	9.3 (5.5–13.8)	0.260
• Platelets (×109/L)	62 (6–388)	42 (7–434)	0.039
• Peripheral myeloblasts (%)	0 (0–18%)	0 (0–15%)	0.051
Bone marrow (BM) findings
• Myeloblasts (%)	3 (0–19%)	4 (0–13%)	0.144
• Cellularity (%)	50 (5–100%)	50 (10–100%)	0.190
• Megakaryocyte numbers
Decreased (≤1/HPF)	41 (37.6%)	4 (9.8%)	<0.001
Normal (2–5/HPF)	28 (25.7%)	8 (19.5%)
Increased (≥6/HPF)	40 (36.7%)	29 (70.7%)
Hepatosplenomegaly	5 (2.3%)	2 (4.4%)	0.343
Constitutional symptoms	24 (11.0%)	9 (20.0%)	0.084
Transfusion dependency	64 (29.0%)	16 (35.6%)	0.243